EASL recommendations on treatment of hepatitis C 2016

European Association for The Study of The Liver - Journal of hepatology, 2017 - Elsevier
Hepatitis C virus (HCV) infection is one of the main causes of chronic liver disease
worldwide [1]. The long-term impact of HCV infection is highly variable, ranging from minimal …

EASL recommendations on treatment of hepatitis C 2018

JM Pawlotsky, F Negro, A Aghemo, M Berenguer… - Journal of …, 2018 - Elsevier
Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with
approximately 71 million chronically infected individuals worldwide. Clinical care for patients …

[HTML][HTML] Like a rolling stone? A review on spontaneous clearance of hepatitis C virus infection

P Rzymski, M Brzdęk, K Dobrowolska, B Poniedziałek… - Viruses, 2024 - mdpi.com
Elimination of hepatitis C virus (HCV) without the need for medical intervention, known as
spontaneous clearance (SC), occurs at a significantly lower rate than in the case of hepatitis …

Hepatitis B virus seroepidemiology data for Africa: Modelling intervention strategies based on a systematic review and meta-analysis

AL McNaughton, J Lourenço, PA Bester… - PLoS …, 2020 - journals.plos.org
Background International Sustainable Development Goals (SDGs) for elimination of
hepatitis B virus (HBV) infection set ambitious targets for 2030. In African populations, infant …

[HTML][HTML] The management of chronic hepatitis C: 2018 guideline update from the Canadian Association for the Study of the Liver

H Shah, M Bilodeau, KW Burak, C Cooper, M Klein… - Cmaj, 2018 - Can Med Assoc
The treatment of hepatitis C has become safer, better tolerated and more effective owing to
the availability of direct-acting antivirals for nearly all patients; this guideline advocates …

Integrated Hepatitis C–Opioid Use Disorder Care Through Facilitated Telemedicine: A Randomized Trial

AH Talal, M Markatou, A Liu, PV Perumalswami… - Jama, 2024 - jamanetwork.com
Importance Facilitated telemedicine may promote hepatitis C virus elimination by mitigating
geographic and temporal barriers. Objective To compare sustained virologic responses for …

Gender differences in liver disease and the drug-dose gender gap

E Buzzetti, PM Parikh, A Gerussi… - Pharmacological Research, 2017 - Elsevier
Although gender-based medicine is a relatively recent concept, it is now emerging as an
important field of research, supported by the finding that many diseases manifest differently …

Peer-assisted telemedicine for hepatitis C in people who use drugs: A randomized controlled trial

A Seaman, R Cook, G Leichtling… - Clinical Infectious …, 2024 - academic.oup.com
Abstract Background Hepatitis C virus (HCV) elimination requires treating people who use
drugs (PWUD), yet< 10% of PWUD in the United States access HCV treatment; access is …

Barriers and facilitators to hepatitis C (HCV) screening and treatment—a description of prisoners' perspective

D Crowley, MC Van Hout, JS Lambert, E Kelly… - Harm Reduction …, 2018 - Springer
Abstract Background Hepatitis C virus (HCV) infection is a global epidemic with an
estimated 71 million people infected worldwide. People who inject drugs (PWID) are …

Risk of hepatocellular carcinoma after spontaneous clearance of hepatitis C virus and in noncirrhosis chronic hepatitis C patients with sustained virological response …

CC Hsu, H Gopalakrishna, M Mironova… - Clinical Infectious …, 2023 - academic.oup.com
In a hepatitis C virus (HCV)–controlled human infection model (CHIM), healthy volunteers
are inoculated with HCV and then treated. Residual hepatocellular carcinoma (HCC) risk …